Last reviewed · How we verify
Rizatriptan 10 mg
At a glance
| Generic name | Rizatriptan 10 mg |
|---|---|
| Also known as | MK-0462, Maxalt |
| Sponsor | Organon and Co |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
- Accidental overdose
- Dizziness
- Somnolence
- Nausea
- Fatigue
- Dry mouth
- Upper respiratory tract infection
- Nasopharyngitis
- Asthenia
- Nausea - Treatment Phase
- Dizziness - Treatment Phase
- Hyperchlorhydria
Key clinical trials
- Efficacy and Safety of Rizatriptan-Naproxen (10/550 Mg) in the Acute Treatment of Migraine (PHASE3)
- Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-072) (PHASE3)
- Study to Test an Approved Product in the Early Treatment of Migraine (0462-066) (PHASE3)
- Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-071) (PHASE3)
- Study to Test an Approved Product in the Early Treatment of Migraine (0462-065) (PHASE3)
- A Study of Rizatriptan for the Treatment of Acute Migraine in Patients on Topiramate for Migraine Prophylaxis (PHASE3)
- A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine (0462-087) (PHASE3)
- A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine in Children and Adolescents (MK-0462-082 AM7) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |